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S U M M A R Y
Twenty-nine stage IIIA/B melanoma patients treated by isolated limb perfusion (ILP) with a high dose of 
recombinant human tumour necrosis factor alpha (rHuTNFa), interferon y (IFNy), and melphalan were histologi­
cally documented with emphasis on therapy-induced changes of the tumour vasculature. Sequential biopsies were 
taken at various intervals before and after the treatment to compare the morphological changes. In order to visualize 
micro vascular changes, immunostaining was performed for von Willebrand factor (VWF), type IV collagen, 
a-smooth muscle actin, endothelial antigen PAL-E, tissue factor, CD41 (thrombocyte marker), and fibrin. In 
biopsies prior to perfusion, necrosis, haemorrhage, and fibrin thrombi were not found. Within 3 h following triple 
combination therapy, a change in the distribution of VWF staining occurred, from a discrete endothelial pattern in 
die untreated lesions to a fuzzy perivascular and subepidermal pattern in the treated lesions. Within 24 h, this was 
accompanied by intravascular thrombocyte aggregation and erythrostasis, in the absence of tissue factor and fibrin 
deposits. These findings indicate that the thrombocyte aggregation observed is not caused by local procoagulant 
activity, but is rather the result of the therapy-associated vascular damage or haemostasis* Although it is difficult to 
derive the dynamics of this process from static images, we assume that TNFa induced endothelial cell damage, 
leading to VWF release. Released VWF may play a role in the adhesion between thrombocytes and the damaged 
endothelium or the denuded subendothelium. As a consequence, the blood flow is impaired, leading to congestion 
and oedema, compatible with an early stage of haemorrhagic infarction.
key w ords—isolated limb perfusion; melanoma; TNFa; VWF; CD41 and thrombocytes
IN T R O D U C T IO N
The aim  of the present study was to investigate 
the hypothesis th a t  the tum our micro vasculature 
is a ta rge t for tum our necrosis factor a (T N F a) 
triple com bination  therapy. Changes in the micro- 
vasculature of the perfused melanoma lesions have 
already been observed, especially the upregulation 
of cellular adhesion molecules . 1 Here we report on
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the m orphological and im m unohistochem ical 
analyses o f  the m icrovascular coagulative events.
T N F a  is a cytokine with pleiotropic actions, 
w ith direct and indirect an titum our effects, and  is 
an im portan t m edia to r of septic shock. Systemic 
adm inistration of T N F a  in cancer patients is 
associated with severe toxicity and negligible an ti­
tu m o u r  effects. Phase I—II studies indicate th a t  the 
m axim al tolerated dose (M T D ) in hum ans is 
±  350 /¿g/m2 in travenously .3 Based on d a ta  in 
m urine tum our models, one m ight expect a dose 10 
to  50 times higher to  be necessary to achieve
Table I—Specification of the biopsy samples
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Melanoma lesions Patients
Cases (n=60) («=29)
Before IFNy s.c. n —6 n - 6
After INFy s.c., but before ILP n -  9 n - 9
After ILP with IFNy, TNFa and melphalan
Early biopsies ^  1 week n -  32 72 = 20
Late biopsies < 1 year n - 10 n - 10
Control patients after ILP with melphalan alone w = 3 n = 3
Table II—The antibodies used
Antibody Specificity Reference
PAL-E endothelium 9,19
A-2547 (Sigma) a-smooth muscle actin 20
MCA 468/S/010 (Serotec) CD41 21
BBA7 (British Bio-Technology) CD31 (PECAM) 22
Tissue factor* tissue factor 23
NKI-BETAB 100 kD melanosome associated glycoprotein 24
KH 58.01POS (CLB) raHu YWF 25
PCO 01403 (Cappel) collagen type IV 26
Po Ab raHu fibrin fibrin 27
*A gift from Dr T. Edgington, MD, The Scrlpps Research Institute, California, U.S.A.
an titu m o u r effects.4 These differences m ay only be 
overcome in the setting o f  isolated limb perfusions
(ILPs).
Isolated limb perfusion for stage III m elanom a 
patients perm its regional cytostatic concentrations 
15 to 20 times higher than  those reached after 
systemic adm inistration. T he  standard  drug in this 
setting is m elphalan  (L-phenyl-alanine mustard). 
IL P  with m elphalan  alone produces a 40-50 per 
cent com plete response ra te  with a m edian dura­
tion of local tu m o u r  contro l for all patients treated 
o f  only 6 m onths . T rue hypertherm ia (>41*5°C) 
m ay improve the response rates, bu t m ay also lead 
to severe regional toxicity. The m odest efficacy o f 
IL P  w ith  m elphalan  alone in stage III m elanom a 
led to  the addition  of high doses of T N F a . The 
results o f  the initial observations in stage III 
m elanom a have recently been published by 
Lienard and  Lejeune .5 Interferon}' (IFNy) is 
added in this schedule because o f  the synergistic 
an ti tu m o u r activity o f  IF N y  plus T N F a .6
In experim ental settings it has been frequently 
repo rted7 th a t  local elicitation o f  endothelial cell 
p roco agu lan t activity by T N F a  leads to the form a­
tion of in travascular thrombi, causing haemostasis 
and  ischaemia in vivo. Alternatively, activation of 
the coagulation cascade or throm bocyte aggrega­
tion m ay be a  consequence o f  induced vascular 
dam age or o f  im pairm ent o f  the blood flow. In 
order to determine whether and to what extent 
these phenom ena occur in m elanom a patients 
treated by ILP, we examined tissue specimens, 
sequentially taken  before and after cytokine 
adm inistration, using histological and immuno- 
histochemical m ethods.
P A T IE N T S  A N D  M E T H O D S
Patient characteristics
M elanom a patients with in-transit metastasis of 
the limbs (stage IIIA ), or with additional regional 
lymph node m etastasis (stage IIIB), with no sign of 
distant metastasis, no  other malignancies, and no 
severe arterial insufficiency were admitted for 
IL P .8 In the three participating institutions (Jules 
Bordet Institute, D r  Daniel den H oed Cancer 
Centre, N K I  Am sterdam ), all patients clinically
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Fig. 1—Histopathological changes after various treatment regimes. (A) Prior to IFNy administration s.c.; 
(B) biopsies taken after IFNy but before ILP
selected for ILP were included in this morphologi­
cal a n d  immunohistochemical study. This study on 
the  microvascular coagulative events comprises the 
b iopsies of 29 m elanom a patients. Other m orpho­
logical phenom ena have been described in 15 
p a t ie n ts  of this group by R enard  et al}
D rugs and treatment schedule1
D rugs— Recom binant hum an T N F a  (0-2 mg/ 
am pou le )  and recom binant hum an IFNy 
(0-2 m g  or 1*5 x 106 U /ampoule) were a gift from 
B oehringer Ingelheim Germany. The cytostatic 
d ru g  melphalan (Alkeran) was obtained as a sterile 
p o w d e r  (100 mg) which was dissolved aseptically 
u s in g  solvent and diluent provided by Burroughs 
W ellcom e (London, U .K .)
Treatm ent schedule— Patients received 0-2 mg 
IF N y  subcutaneously  (s.c.) on  the 2 days prior to 
the ILP. IL P  consisted o f  a 1-5 h long  perfusion 
with 0*2 m g IF N y , 2 or 3 (arm )-4  m g (leg) TN Fa, 
and  10 mg/1 leg o r  13 mg/1 a rm  volum e of mel­
p h a lan  a t mild hypertherm ia  (40°C). IFNy and 
T N F a  were injected successively as a  bolus into 
the arterial line. M elphalan  w as administered 30 
m in later. A t  the  end  of ILP , the  limb was 
w ashed tho rough ly  with R in g e r’s solution, 
H aem accel, and /o r  6 p e r  cent dex tran  up to 4 1. 
Leakage o f  the drugs was m easured  with radio- 
iod inated  h u m an  serum  albumin. Preoperatively 
and  postoperatively  dopam ine  was administered 
in a b o u t ha lf  o f  the  patien ts  at 2 /zg/kg per min 
by continuous infusion, usually for several hours 
up  to 48 h. F lu id  loading was applied before
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A. Early biopsies (n = 32)
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Fig. 2—Biopsies taken at various time points after perfusion with TNFa, IFNy, and melphalan. (A) Early biopsies; 
(B) late biopsies
VWF RELEASE AND PLATELET AGGREGATION IN HUMAN MELANOMA 283
Score
+ +
+
+
0
COO
0 0 0 000
0
0 0 000 000
platelet fibrin necrosis oedema haemo- inflammatory
aggregation thrombi rrhage infiltrate
Fig. 3—Biopsies in patients after perfusion with melphalan alone
releasing the tourn iquet after the completion of 
washing.
Tissue specimens— Oral informed consent 
was obtained from  the patients to take sequential 
biopsies. Sixty biopsies from  29 patients were 
snap-frozen and stored at — 80°C until use. From  
15 patients, besides frozen tissue, tissue samples 
were also taken to  be em bedded in paraffin after 
fo rm alin  fixation. The histological material con­
sisted o f biopsies taken before the administration 
o f  IF N y  s.c., after IFN y s.c. bu t before ILP with 
IFN> T N F a  and m elphalan, and  at various time 
p o in ts  after perfusion (Table I).
L ig h t  microscopy
Consecutive 4 jum sections were cut and stained 
w ith  haematoxylin and eosin. Besides documenta­
t io n  o f  the pathological diagnosis, the following 
histopathological features were assessed semi- 
quantitatively: necrosis (coagulative and/or haem- 
orrhagic), throm bocyte aggregation (visualized by 
im m unohistochem istry), fibrin thrombi, oedema, 
haem orrhage, and inflammatory infiltrate. The 
semi-quantitative grading used was as follows:
0 =  n o  change; ±  = sporadic event; + = local event; 
+ +  =  generalized event.
T h e  following antigens were studied in 4/zm 
frozen  sections: endothelial antigen PAL-E, tissue 
fac to r ,  CD41 (thrombocytes), and a-smooth 
m uscle  actin (pericytes and  sm ooth  muscle cells).
T h e  following antigens were studied in 4 /im  
paraffin  or frozen sections: von Willebrand factor, 
type  IV collagen, fibrin, CD31 (PECAM), and 
100 k D  melanosome-associated glycoprotein.
T he antibodies used are  listed in Table II.
T he  expression o f  the above antigens was deter­
m ined on the  m icrovasculature in the centre o f  the 
tum our, a t  the edge o f  the  tum our, adjacent to the 
tum our, and  within the tu m o u r  cells. Staining was 
perfo rm ed  using an indirect immunoperoxidase 
procedure, em ploying am ino-ethylcarbazole as 
chrom ogen. Sections were counterstained with 
H arris  haem atoxylin . T h e  semi-quantitative grad­
ing included b o th  intensity (negative: -  to highly 
positive: +  + ) an d  estim ated percentage of positive 
cells (score 0 = 0 -5  per  cent; 1 = 6-25  per cent; 
2=  26-50 per cent; 3 =  51-75 per cent; 4 = 76-100 
per cent). The slides were read  by two different 
observers. In cases o f  disagreement, consensus was 
reached during  jo in t  re-exam ination.
R E S U L T S
A n upda te  o f  the clinical results o f  the ILP 
trea tm en t has been recently re p o r te d .8
T he histological changes after various treatment 
regimes are show n in Fig. 1 ( A = before IFNy s.c.; 
B =  after IF N y  s.c. bu t before ILP), 2 (various time 
poin ts  after ILP  with IFN y, T N F a ,  and mel- 
phalan), and  3 (after IL P  with m elphalan  alone)
Biopsies p rio r to  IF N y  s.c. (n = 6) showed no 
evidence o f  necrosis, haem orrhage or fibrin 
th rom bi, a lthough  sporad ic  in travascular throm ­
bocyte aggregation cou ld  be detected at the 
periphery  o f  un trea ted  tum ours  (Fig. 1A). After 
IF N y  s.c., b u t  before IL P  w ith  T N F a  and mel­
pha lan , a slight increase in th rom bocy te  aggrega­
tion  (three out o f  nine) occurred (Fig. IB). Within 
a  period  of 24 h  after complete treatment, a 
m arked  increase in th rom bocyte  aggregation was 
observed in all biopsies ( n - 2 2 , Fig. 2A). The 
extent of the aggregates varied from  local to a
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generalized involvement of the tum our micro- 
vasculature, both  in the centre and at the periphery 
o f  the  tumour. This occurred without significant 
fibrin staining or haem orrhage, although dermal 
oedem a and erythrostasis in the microvessels were 
frequently recorded. After 1 week, the CD41- 
positive aggregates persisted and extensive necrosis 
occurred  (five out o f  ten lesions, Fig. 2). Necrosis 
was o f  the coagulative type, with or without haem- 
orrhag ic  elements. This was less obvious in 
tu m o u rs  taken from  patients who did not develop 
a com plete response. Oedem a was frequently 
recorded  and was m aintained for several weeks. In 
one patient, throm bocyte aggregation could still be 
observed in a biopsy 9 m onths after perfusion (Fig. 
2B). M elanom a lesions (« =  3, Fig. 3) treated with 
m elphalan  perfusion alone revealed thrombocyte 
aggregation but in these patients it was never 
associated with necrosis.
T h e  sequential immunohistochemical analysis 
revealed a m arked change in the distribution of 
V W F  staining after complete perfusion treatment 
as com pared  with the pretreatm ent biopsies. Prior 
to IF N y  s.c., V W F  staining was confined to the 
endothelial layer (+  + + , 76-100 per cent), both in 
n o rm a l  skin and in the m elanom a lesions. H alf an 
h o u r  after ILP with IFNy, T N F a , and melphalan, 
a slight increase in perivascular staining was 
observed in the m elanom a lesions (+ ,  76-100 per 
cent). Although the V W F  staining in the skin 
ou ts ide  the m elanom a lesion was confined to the 
endothelial layer, m arked subepidermal and 
perivascular V W F staining was recorded in and 
ab o v e  the m elanom a lesions 3 h after complete 
perfusion  (Figs 4A and 4B) (+ ,  76-100 per cent). 
T h is  was accompanied within a period of 24 h 
by intravascular throm bocyte aggregation (Figs 
4 C -4 E ) ,  erythrostasis, and meshwork-like intra­
vascu la r  VW F staining (not shown). In the tumour 
cen tre , a decrease o f  a-sm ooth  muscle actin (+ , 
6 -2 5  per cent) and type IV collagen (+ , 6-25 per 
cent) staining in the microvascular walls could be 
observed. The PA L-E  endothelial staining became 
discontinuous, in com parison with the circular 
endothelia l staining in the peritumoral and 
u n tre a te d  tissues (not shown). Tissue factor stain­
ing o f  the endothelium  w as negative in all cases, in 
co n tras t  w ith the  positive stain ing of the adventi­
tial vascular cells and  ep iderm al and sweat gland 
epithelial cells in the  same sections. Identically 
trea ted  sections o f  a sq u am o us  cell carcinoma 
specimen and  o f  n o rm a l rena l glomeruli were 
regarded  as positive controls fo r  the tissue factor 
stain ing procedure.
D IS C U S S IO N
T N F a  in com b in a tio n  w ith  melphalan and 
IF N y , adm inistered  in an  isolated limb perfusion 
setting, has been show n to  increase the number of 
com plete remissions and  the du ra tion  of response 
in stage IIIA /B m elan o m a patients as compared 
w ith perfusion w ith  m elphalan  alone .5 Changes in 
the m icrovasculature  o f  the perfused melanoma 
lesions were observed, especially the upregulation 
o f  cellular adhesion m olecules . 1 Here we report 
on the m orphological and  immunohistochemical 
analyses o f  the m icrovascular coagulative events, 
w ith visualization of s truc tu ra l and functional 
m arkers  o f  the endo the lium .9
Sequential biopsies tak en  before and at various 
tim e poin ts  after cy tokine adm inistration revealed 
a  m ark ed  change in the  distribution of VW F 
staining. Before IF N y  s.c., V W F  staining was 
confined to  the endothelial layer. Marked sub- 
epiderm al and perivascular V W F  staining was 
recorded 3 h  after com plete perfusion. This was 
accom panied  w ithin  a  period o f  24 h by intra­
vascular th rom bocy te  aggregation, erythrostasis, 
and  in travascular m eshw ork-like VW F staining. 
These findings strongly suggest that the tumour 
m icrovasculature  is the  m ain  target in human 
m elanom a in transit m etastasis treated with a high 
dose o f  rH u -T N F a  in co m b in a tio n  with IFNy and 
m elphalan . O bservations in late biopsies (range to 
9 m onths after perfusion) m ay indicate that, apart 
from  an acute event, the tu m o u r  microvasculature 
m ay  have undergone long-lasting damage.
Over the last few years, interest in von 
W illebrand fac tor (V W F) as a marker of endo­
thelial cell injury has been grow ing .10 VW F is
Fig. A— (A) VWF immunostaining in a frozen section of skin, in the vicinity of a melanoma metastasis, 3 h after perfusion with 
IFN)», TNFa, and melphalan. (e = Epidermis; d=dermis.) (B) VWF immunostaining in a frozen section of skin with melanoma 
metastasis 3 h after perfusion with TNFa, IFN}’, and melphalan. (c = Epidermis; d=dermis.) (C,D) Double immunostaining for 
VWF (brown) and CD41 (dark blue) in a frozen section of skin with melanoma metastasis 24 h after perfusion with TNFa, IFNy, 
and melphalan. (e=Epidermis; d = dermis.) (E) Double immunostaining for VWF (brown) and CD41 (dark blue) in a frozen section 
of skin with melanoma metastasis in an area of necrosis, 24 h after perfusion with TNFa, IFN)\ and melphalan. (n-Necrosis)
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synthesized by endothelial cells and m egakaryo­
cytes and can be stored in endothelial-specific 
W eibel-Paiade  bod ies 11 an d  in the a granules o f 
the platelet. The role o f  V W F in the adhesion and 
aggregation process can be looked upon  as bridge 
fo rm ation  between the throm bocytes and the sub- 
endothelium  o f  the injured vessel wall. 
Accordingly, V W F  can bind with throm bocyte 
m em brane  glycoproteins lb  and Ilb /IIIa  (CD41/ 
CD42) and  com ponents  o f  the subendothelium, 
such as collagen.
T N F  and o ther cytokines m ay well play a role in 
the release o f  V W F  by endothelial cells, bo th  in 
vitro and in vivo. Alternatively, as stated by Paleolo 
et al. ,15 they m ight have no  direct effect on V W F 
release b u t  can significantly m odulate  its acute 
release in response to  th rom bin  in a complex time- 
and dose-dependent m anner. Van der Poll et al. 
investigated the effect o f  T N F  011 the release of 
V W F  into the circulation during a controlled study 
in six healthy men, sequentially measuring the 
p lasm a concentrations o f  V W F  after a bolus in tra ­
venous injection o f  recom binan t hum an T N F a  
(50/ig /m 2) .16 T N F a  induced a m arked increase in 
V W F  antigen p lasm a levels, becoming significant 
after 45 m in and  peaking after 4 h. The multimeric 
organization o f circulating V W F  was not affected 
by T N F a . We observed slight perivascular V W F 
im m unostain ing  within 30 min after IL P  
(T N F a + m e lp h a la n  + IFN y) and pronounced stain­
ing a t 3 h. M eshwork-like intralum inal V W F stain­
ing, erythrostasis, and throm bocyte  aggregations 
could be observed within a period o f  24 h after 
ILP.
N aw ro th  et aL dem onstra ted  tha t infusion of 
low concentrations o f  T N F a  (3/ig/anim al) into 
mice bearing m eth-A -fibrosarcom as leads to local­
ized fibrin deposition w ith the form ation  o f  occlu­
sive in travascular th rom b i in close association with 
the endothelial cell surface .7 They proposed  a 
coagulation cascade starting  with induction of 
tissue factor by T N F a .  Tissue factor, also know n 
as tissue th rom boplastin , is a cell surface glyco­
protein  responsible for triggering the extrinsic 
pa thw ay  o f  the coagulation  cascade . 17 Induction  
o f  tissue factor expression on the endothelium  has 
been reported  after in vitro incubation with 
T N F a . 18
All o f  these earlier results were found  in an 
experim ental setting. H av ing  studied biopsies from  
patien ts  trea ted  w ith ILP , however, we were 
unable  to find an  increase in fibrin deposition 
in the  tu m o u r  vascu lar bed, o r  positive im m uno-
staining o f  the endothelial cells for tissue factor. 
F ixation-related denaturation  o f  tissue factor 
could n o t  explain the negative staining results in 
the m elanom a lesions, because in the same sections 
adventitial vascular cells and epidermal and sweat 
gland epithelial cells stained positive as internal 
controls. Also, in alignment with the results 
described by R a o ,23 we found positive staining of 
identically treated squamous cell carcinoma and 
norm al renal glomeruli.
The increase of perivascular V W F  distribution 
and  CD41 -positive throm bocyte aggregations 
associated w ith the (sub)endothelial cell surface, 
together w ith  the absence of tissue factor and fibrin 
staining, indicates that throm bocyte aggregation is 
no t due to local procoagulant activity, but is rather 
the result of the induced vascular damage or 
haemostasis, TN Fa-induced congestion, haemor­
rhage, and  oedema m ay represent an impaired 
b lood flow, finally leading to haemorrhagic infarc­
tion. Platelet aggregation may enhance congestion 
and  thereby accelerate the occurrence of haemor­
rhagic infarction. During this process, VW F may 
play an  im portan t role in the adhesion between 
throm bocytes and the subendothelium. In addi­
tion, granulocytes may contribute to the endo­
thelial cell damage. In the current patient group, 
a significant influx of granulocytes was not 
consistently observed, in contrast to thrombocyte 
aggregation. Granulocyte-mediated damage may 
therefore be o f  importance, bu t does no t seem to 
be a sine qua non. It can be concluded, however, 
tha t all findings support the assumption that the 
tum our microvasculature is an im portant target 
for T N F a  triple combination therapy.
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